420 related articles for article (PubMed ID: 24574393)
1. Mitophagy enhances oncolytic measles virus replication by mitigating DDX58/RIG-I-like receptor signaling.
Xia M; Gonzalez P; Li C; Meng G; Jiang A; Wang H; Gao Q; Debatin KM; Beltinger C; Wei J
J Virol; 2014 May; 88(9):5152-64. PubMed ID: 24574393
[TBL] [Abstract][Full Text] [Related]
2. [Synergistic Effect of NF-κB Signaling Pathway Inhibitor and Oncolytic
Measles Virus Vaccine Strain against Lung Cancer and Underlying Mechanisms].
Xia M; Meng G; Dong J
Zhongguo Fei Ai Za Zhi; 2021 Apr; 24(4):245-253. PubMed ID: 33775041
[TBL] [Abstract][Full Text] [Related]
3. Mitophagy switches cell death from apoptosis to necrosis in NSCLC cells treated with oncolytic measles virus.
Xia M; Meng G; Jiang A; Chen A; Dahlhaus M; Gonzalez P; Beltinger C; Wei J
Oncotarget; 2014 Jun; 5(11):3907-18. PubMed ID: 25004098
[TBL] [Abstract][Full Text] [Related]
4. Attenuated oncolytic measles virus strains as cancer therapeutics.
Msaouel P; Iankov ID; Dispenzieri A; Galanis E
Curr Pharm Biotechnol; 2012 Jul; 13(9):1732-41. PubMed ID: 21740361
[TBL] [Abstract][Full Text] [Related]
5. Oncolytic measles virus enhances antitumour responses of adoptive CD8
Chen A; Zhang Y; Meng G; Jiang D; Zhang H; Zheng M; Xia M; Jiang A; Wu J; Beltinger C; Wei J
Sci Rep; 2017 Jul; 7(1):5170. PubMed ID: 28701757
[TBL] [Abstract][Full Text] [Related]
6. Measles to the Rescue: A Review of Oncolytic Measles Virus.
Aref S; Bailey K; Fielding A
Viruses; 2016 Oct; 8(10):. PubMed ID: 27782084
[TBL] [Abstract][Full Text] [Related]
7. Dichloroacetate blocks aerobic glycolytic adaptation to attenuated measles virus and promotes viral replication leading to enhanced oncolysis in glioblastoma.
Li C; Meng G; Su L; Chen A; Xia M; Xu C; Yu D; Jiang A; Wei J
Oncotarget; 2015 Jan; 6(3):1544-55. PubMed ID: 25575816
[TBL] [Abstract][Full Text] [Related]
8. Forskolin Enhances Antitumor Effect of Oncolytic Measles Virus by Promoting Rab27a Dependent Vesicular Transport System.
Xia M; Wang Y; Xia Y; Zeng J
Curr Microbiol; 2024 Feb; 81(4):93. PubMed ID: 38334775
[TBL] [Abstract][Full Text] [Related]
9. Engineered measles virus as a novel oncolytic therapy against prostate cancer.
Msaouel P; Iankov ID; Allen C; Morris JC; von Messling V; Cattaneo R; Koutsilieris M; Russell SJ; Galanis E
Prostate; 2009 Jan; 69(1):82-91. PubMed ID: 18973133
[TBL] [Abstract][Full Text] [Related]
10. Engineered measles virus as a novel oncolytic viral therapy system for hepatocellular carcinoma.
Blechacz B; Splinter PL; Greiner S; Myers R; Peng KW; Federspiel MJ; Russell SJ; LaRusso NF
Hepatology; 2006 Dec; 44(6):1465-77. PubMed ID: 17133484
[TBL] [Abstract][Full Text] [Related]
11. Targeted release of oncolytic measles virus by blood outgrowth endothelial cells in situ inhibits orthotopic gliomas.
Wei J; Wahl J; Nakamura T; Stiller D; Mertens T; Debatin KM; Beltinger C
Gene Ther; 2007 Nov; 14(22):1573-86. PubMed ID: 17898797
[TBL] [Abstract][Full Text] [Related]
12. MAVS-dependent IRF3/7 bypass of interferon β-induction restricts the response to measles infection in CD150Tg mouse bone marrow-derived dendritic cells.
Takaki H; Honda K; Atarashi K; Kobayashi F; Ebihara T; Oshiumi H; Matsumoto M; Shingai M; Seya T
Mol Immunol; 2014 Feb; 57(2):100-10. PubMed ID: 24096085
[TBL] [Abstract][Full Text] [Related]
13. LRRC59 modulates type I interferon signaling by restraining the SQSTM1/p62-mediated autophagic degradation of pattern recognition receptor DDX58/RIG-I.
Xian H; Yang S; Jin S; Zhang Y; Cui J
Autophagy; 2020 Mar; 16(3):408-418. PubMed ID: 31068071
[TBL] [Abstract][Full Text] [Related]
14. Graphene oxide arms oncolytic measles virus for improved effectiveness of cancer therapy.
Xia M; Luo D; Dong J; Zheng M; Meng G; Wu J; Wei J
J Exp Clin Cancer Res; 2019 Sep; 38(1):408. PubMed ID: 31533779
[TBL] [Abstract][Full Text] [Related]
15. Sensitivity of human pleural mesothelioma to oncolytic measles virus depends on defects of the type I interferon response.
Achard C; Boisgerault N; Delaunay T; Roulois D; Nedellec S; Royer PJ; Pain M; Combredet C; Mesel-Lemoine M; Cellerin L; Magnan A; Tangy F; Grégoire M; Fonteneau JF
Oncotarget; 2015 Dec; 6(42):44892-904. PubMed ID: 26539644
[TBL] [Abstract][Full Text] [Related]
16. Oncolytic measles viruses for cancer therapy.
Nakamura T; Russell SJ
Expert Opin Biol Ther; 2004 Oct; 4(10):1685-92. PubMed ID: 15461580
[TBL] [Abstract][Full Text] [Related]
17. Measles virus selectively blind to signaling lymphocyte activation molecule as a novel oncolytic virus for breast cancer treatment.
Sugiyama T; Yoneda M; Kuraishi T; Hattori S; Inoue Y; Sato H; Kai C
Gene Ther; 2013 Mar; 20(3):338-47. PubMed ID: 22717740
[TBL] [Abstract][Full Text] [Related]
18. PACT- and RIG-I-Dependent Activation of Type I Interferon Production by a Defective Interfering RNA Derived from Measles Virus Vaccine.
Ho TH; Kew C; Lui PY; Chan CP; Satoh T; Akira S; Jin DY; Kok KH
J Virol; 2016 Feb; 90(3):1557-68. PubMed ID: 26608320
[TBL] [Abstract][Full Text] [Related]
19. Cell-type-specific innate immune response to oncolytic Newcastle disease virus.
Biswas M; Kumar SR; Allen A; Yong W; Nimmanapalli R; Samal SK; Elankumaran S
Viral Immunol; 2012 Aug; 25(4):268-76. PubMed ID: 22808996
[TBL] [Abstract][Full Text] [Related]
20. Type 1 Interferon Responses Underlie Tumor-Selective Replication of Oncolytic Measles Virus.
Aref S; Castleton AZ; Bailey K; Burt R; Dey A; Leongamornlert D; Mitchell RJ; Okasha D; Fielding AK
Mol Ther; 2020 Apr; 28(4):1043-1055. PubMed ID: 32087150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
